Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Bratisl Lek Listy ; 116(7): 440-5, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26286247

RESUMEN

BACKGROUND: As shown in several studies, besides being used in breast cancer, tamoxifen is also known for its antifibrotic effects via reducing the serum TGF-beta levels. We investigated the possible preventive effect of tamoxifen in rats exposed to silica particles depending on the antifibrotic effect. MATERIALS AND METHODS: A total of 102 adult female Wistar Albino rats were divided into five groups. First two groups (control and tmx) were free of silica and the last three groups (slc, tmx1 and tmx 10) were exposed to crystalline silica. The rats in tmx, tmx1 and tmx10 groups received 10 mg/kg, 1 mg/kg and 10 mg/kg of body weight tamoxifen, respectively. On day 84, all rats were sacrified and tissue samples were obtained together with blood samples. The differences in serum TGF-ß levels, histological grades of fibrosis and inflammation in the lung and liver tissues together with addional biochemical markers were calculated between the groups. RESULTS: Silicosis occurred in slc, tmx1 and tmx10 groups in 100%, 91.7% and 52.1%, respectively. Liver fibrosis did not occur. The highest mean lung fibrosis scores were obtained in slc group while the scores were lower in tmx1 group and the lowest in tmx10 within silica-exposed rats. Nevertheless, the inflammation scores were higher in tamoxifen-administered rats in a dose-dependent pattern. CONCLUSION: Silica inhalation did not result in liver fibrosis. Tamoxifen is found to prevent lung fibrosis and reduce serum TGFß-1 levels while increasing lung inflammation (Tab. 3, Fig. 3, Ref. 27).


Asunto(s)
Fibrosis Pulmonar/prevención & control , Dióxido de Silicio/toxicidad , Silicosis/tratamiento farmacológico , Tamoxifeno/farmacología , Animales , Femenino , Exposición por Inhalación , Hígado/efectos de los fármacos , Hígado/patología , Pulmón/efectos de los fármacos , Pulmón/patología , Fibrosis Pulmonar/tratamiento farmacológico , Fibrosis Pulmonar/patología , Ratas , Ratas Wistar , Silicosis/patología , Factor de Crecimiento Transformador beta1/metabolismo
2.
Transplant Proc ; 47(3): 836-40, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25891742

RESUMEN

Acute fibrinous and organizing pneumonia (AFOP) is a distinct histologic pattern usually classified under the term chronic lung allograft dysfunction. We present a 48-year-old female patient who experienced AFOP during the 2nd week of double lung transplantation for pulmonary Langerhans cell histiocytosis and secondary pulmonary hypertension. During the 8th day after transplantation, fever and neutrophilia developed together with bilateral consolidation. Infection markers were elevated. Despite coverage of a full antimicrobial spectrum, the situation progressed. The patient was diagnosed with AFOP with transbronchial biopsy. The infiltration resolved and the patient improved dramatically with the initiation of pulse corticosteroid treatment. AFOP should be suspected when there is a pulmonary consolidation after lung transplantation, even in the very early post-transplantation period. Several causes, such as alveolar damage and drug reactions, should be considered in the differential diagnosis.


Asunto(s)
Trasplante de Pulmón , Neumonía/patología , Progresión de la Enfermedad , Oxigenación por Membrana Extracorpórea , Femenino , Fibrosis , Rechazo de Injerto , Humanos , Pulmón/patología , Trasplante de Pulmón/efectos adversos , Persona de Mediana Edad , Neumonía/diagnóstico por imagen , Neumonía/etiología , Periodo Posoperatorio , Quimioterapia por Pulso , Radiografía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...